How can the risk that orphan drugs present to budgets be managed better?
作者信息
O'Neill Ciaran
出版信息
Clin Ther. 2010 Aug;32(9):1640-1. doi: 10.1016/j.clinthera.2010.08.007.
Abstract
摘要
相似文献
1
How can the risk that orphan drugs present to budgets be managed better?
Clin Ther. 2010 Aug;32(9):1640-1. doi: 10.1016/j.clinthera.2010.08.007.
2
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006.
3
[Medication: 15 years 'EU-directive orphan drugs'].
Bull Cercle Benelux Hist Pharm. 2015 Mar(128):21-6.
4
Access to orphan drugs in Europe: current and future issues.
Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):23-9. doi: 10.1586/erp.11.95.
5
Duel over discounts. Pharma, providers at odds over 'orphan drugs'.
Mod Healthc. 2012 Jan 23;42(4):30-1.
6
[Orphan drugs: availability, reliability and reimbursement].
Ned Tijdschr Geneeskd. 2012;156(17):A4252.
7
Support system: through charities, drug makers help people--and themselves.
Wall St J (East Ed). 2005 Dec 1:A1, A10.
8
Lucrative niches: how drugs for rare diseases became lifeline for companies.
Wall St J (East Ed). 2005 Nov 15:A1, A18.
9
Limits on use of health economic assessments for rare diseases.
QJM. 2014 Mar;107(3):241-5. doi: 10.1093/qjmed/hcu016. Epub 2014 Jan 22.
10
[Authorization and reimbursement of orphan drugs in an international comparison].
Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16.
Zotero 插件